Videos

“Health care disparities are very complex issues; it’s not like a linear cause-and-effect relationship,” says Elisabeth M. Sebesta, MD.

Dr. Sebesta discusses disparities in incontinence product usage, costs

“[We] found that women were spending on average, nearly $35 a week on incontinence products in the highest symptom severity, which is a huge financial burden,” says Elisabeth M. Sebesta, MD.

Researchers evaluate incontinence product usage and costs

“With an increase in medical and surgical therapies in younger individuals, health care providers must discuss fertility preservation options prior to affirmation therapy,” says Niki Parikh, MD, MBA, MSBA.

Dr. Niki Parikh on transgender fertility care

“What we did find is that UGN-102 did not cause decrements in patient-reported urinary symptoms, bloating, flatulence, or malaise at the primary trial end point of 3 months,” says Angela M. Stover, PhD.

Study explores patient-reported outcomes for UGN-102 in NMIBC

“These are men who are suffering in silence. Many of them are too embarrassed to ever discuss their sexual health problems,” says Mohit Khera, MD, MBA, MPH.

What survey findings reveal about men’s sexual health

“We were surprised that only 43% of individuals believed fertility preservation to be important, but this could be due to the relatively low age of our respondents, with the majority being between 18 and 39 years old,” says Niki Parikh, MD, MBA, MSBA.

Study points to deficiency in transgender fertility care

“It's really the overall excellence of a multidisciplinary program focused on improving patient outcomes,” says Daniel E. Spratt, MD.

Dr. Shoag and Dr. Spratt discuss SpaceOAR Center of Excellence distinction

“There will always be changes. I'm entering my fourth cycle of recertification, and I can tell you that none of the 3 prior cycles were similar,” says David Joseph, MD.

Dr. Joseph on what to expect from proposed ABU Lifelong Learning Program changes

“Guidelines are not a rulebook; they're a framework for how to think about a particular disease,” says Edward M. Schaeffer, MD, PhD.

Dr. Schaeffer on utilizing the NCCN’s guidelines for prostate cancer

"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

UTv Videos